A detailed history of Seven Eight Capital, LP transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Seven Eight Capital, LP holds 7,404 shares of SRPT stock, worth $880,853. This represents 0.09% of its overall portfolio holdings.

Number of Shares
7,404
Previous 24,684 70.0%
Holding current value
$880,853
Previous $3.9 Million 76.31%
% of portfolio
0.09%
Previous 0.42%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$124.33 - $156.75 $2.15 Million - $2.71 Million
-17,280 Reduced 70.0%
7,404 $924,000
Q2 2024

Aug 12, 2024

BUY
$113.33 - $163.85 $1.86 Million - $2.69 Million
16,405 Added 198.15%
24,684 $3.9 Million
Q1 2024

May 13, 2024

BUY
$93.7 - $141.53 $218,321 - $329,764
2,330 Added 39.17%
8,279 $1.07 Million
Q4 2023

Feb 13, 2024

BUY
$67.31 - $124.76 $400,427 - $742,197
5,949 New
5,949 $573,000
Q4 2022

Feb 13, 2023

BUY
$100.86 - $132.13 $229,960 - $301,256
2,280 New
2,280 $295,000
Q4 2020

Feb 09, 2021

SELL
$125.56 - $178.74 $213,452 - $303,858
-1,700 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$127.12 - $172.34 $216,104 - $292,978
1,700 New
1,700 $239,000
Q1 2020

May 14, 2020

SELL
$82.38 - $131.64 $4.25 Million - $6.79 Million
-51,574 Closed
0 $0
Q4 2019

Feb 13, 2020

SELL
$76.53 - $135.58 $84,183 - $149,138
-1,100 Reduced 2.09%
51,574 $6.66 Million
Q3 2019

Nov 14, 2019

BUY
$72.81 - $156.91 $3.84 Million - $8.27 Million
52,674 New
52,674 $3.97 Million
Q3 2018

Oct 18, 2018

SELL
$115.31 - $161.51 $5.86 Million - $8.21 Million
-50,854 Closed
0 $0
Q2 2018

Aug 07, 2018

BUY
$71.74 - $153.69 $3.65 Million - $7.82 Million
50,854 New
50,854 $6.72 Million
Q3 2017

Oct 16, 2017

SELL
$35.73 - $47.15 $665,078 - $877,650
-18,614 Closed
0 $0
Q2 2017

Aug 10, 2017

BUY
N/A
18,614
18,614 $627,000

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10.4B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Seven Eight Capital, LP Portfolio

Follow Seven Eight Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Seven Eight Capital, LP with notifications on news.